Evotec (ETR:EVT) Trading Up 0.2% – Time to Buy?

Evotec SE (ETR:EVT)’s stock price rose 0.2% during trading on Tuesday . The stock traded as high as €5.20 and last traded at €5.15. Approximately 304,965 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 1,360,000 shares. The stock had previously closed at €5.14.

Evotec Trading Up 0.2%

The company has a quick ratio of 2.97, a current ratio of 1.68 and a debt-to-equity ratio of 55.38. The stock’s 50 day moving average price is €4.97 and its 200-day moving average price is €5.28. The stock has a market capitalization of $955.56 million, a P/E ratio of -5.57, a P/E/G ratio of 0.98 and a beta of 1.31.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.